-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
2 views
WASHINGTON, April 17, 2025 (GLOBE NEWSWIRE) -- Investors who lost money on securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) purchased pursuant and/or traceable to the Zenas BioPharma's September 2024 initial public offering (the “IPO”) are encouraged to contact Cohen Milstein Sellers & Toll PLLC to learn about a recently filed securities class action lawsuit. [ Click here for information about joining the class action ] CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies.
